In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab

BACKGROUND: The impact of disease-modifying therapies on the efficacy to mount appropriate immune responses to COVID-19 vaccination in patients with multiple sclerosis (MS) is currently under investigation. OBJECTIVE: To characterize long-term humoral and cellular immunity in mRNA-COVID-19 MS vaccin...

Descripción completa

Detalles Bibliográficos
Autores principales: Achiron, Anat, Mandel, Mathilda, Dreyer-Alster, Sapir, Magalashvili, David, Menascu, Shay, Warszawer, Yehuda, Dolev, Mark, Didikin, Maria, Harari, Gil, Sonis, Polina, Falb, Rina, Gurevich, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008178/
https://www.ncbi.nlm.nih.gov/pubmed/36933299
http://dx.doi.org/10.1016/j.msard.2023.104616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008178/
https://www.ncbi.nlm.nih.gov/pubmed/36933299
http://dx.doi.org/10.1016/j.msard.2023.104616

Ejemplares similares